Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice

BACKGROUND: Current clinical trials are using radiation therapy (RT) to enhance an antitumor response elicited by high-dose interleukin (IL)-2 therapy or immune checkpoint blockade (ICB). Bempegaldesleukin (BEMPEG) is an investigational CD122-preferential IL-2 pathway agonist with prolonged in vivo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Pieper, Alexander A, Rakhmilevich, Alexander L, Spiegelman, Daniel V, Patel, Ravi B, Birstler, Jen, Jin, Won Jong, Carlson, Peter M, Charych, Deborah H, Hank, Jacquelyn A, Erbe, Amy K, Overwijk, Willem W, Morris, Zachary S, Sondel, Paul M
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Clinical/Translational Cancer Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8237721/
https://ncbi.nlm.nih.gov/pubmed/34172518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002715
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars